HOMEPAGE
Fully Diluted Subscribe

NYSE · Biotech stocks database

LLY — Eli Lilly and Company

LLY (Eli Lilly and Company) stock: $1,354.49, $1274.23B market cap, $4.88B cash, $1318.85B EV, $1210.51B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products. Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.

Source: 10-K FY2025 via SEC EDGAR

Share price
$1,354.49
Market cap
$1,274,229.7M
Cash
$4,885.0M
Enterprise value
$1,318,847.7M

Balance sheet

Cash$4,885.0M
Debt$49,503.0M
Net cash-$44,618.0M
Enterprise value$1,318,847.7M
Basic shares893.7M shares
Fully diluted shares893.7M shares
Fully diluted market cap$1,210,507.7M
Cash per share$5.47
Quarterly burn+$10,690.0M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common
893.7M
Pre-funded warrants
—
Options
—
RSUs
—
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
893.7M

Cap table as of 2026-06-30.

Price history

Loading LLY daily closes…

Loading price history…

Next catalyst

LY3650150 · Now - Nov 24, 2026 Now · Phase 3 · Perennial Allergic Rhinitis (PAR)

Recently reported

Retatrutide Phase 3 Positive · 2026-10-28
TRANSCEND-T2D-2 · type 2 diabetes
Primary: Change in A1C at 80 weeks (primary objective: retatrutide 12 mg noninferior to Ozempic 2 mg in A1C reduction) — -2.2% (retatrutide 9 mg) and -2.2% (retatrutide 12 mg) vs -1.8% (Ozempic 2 mg), from an average baseline A1C of 8.3%
· Percent change in body weight at 80 weeks: -19.5% (-20.1 kg; -44.3 lbs) at 9 mg and -20.9% (-21.5 kg; -47.4 lbs) at 12 mg vs -9.4% (-9.5 kg; -20.9 lbs) with Ozempic 2 mg (p<0.001 vs Ozempic for family-wise controlled comparisons)
· Retatrutide met the primary and all key secondary endpoints
· 1,298 adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor, randomized 2:2:1; average baseline body weight 102.4 kg (225.8 lbs; BMI 36.8 kg/m2)
· Retatrutide delivered greater improvements than Ozempic across certain cardiovascular risk factors, including non-HDL cholesterol, triglycerides and systolic blood pressure
· Dysesthesia incidence 4.8% (9 mg), 6.5% (12 mg) vs 2.7% (Ozempic); urinary tract infections 5.8%, 4.2% vs 5.8%
· TRANSCEND-T2D-2 marks the sixth Phase 3 trial in which retatrutide has delivered powerful efficacy
Safety: Most common adverse events were gastrointestinal: diarrhea 28.3%, 32.7% vs 26.4%, nausea 21.2%, 23.8% vs 21.3% (retatrutide 9 mg, 12 mg vs Ozempic); most events mild to moderate; treatment discontinuation due to adverse events 4.8%, 7.9% vs 2.7%
Source release →
Olomorasib Phase 1/2 Positive · 2026-10-25
LOXO-RAS-20001
Source release →
Sofetabart Mipitecan Phase 1 Positive · 2026-10-24
Source release →
Mirikizumab Phase 3 Positive · 2026-10-19
SHINE-2
Primary: Clinical remission at Week 52 among Week 12 clinical responders (SHINE-2, single-arm open-label Phase 3, pediatric UC ages 6 to 17, N=52 responders of 63 enrolled), evaluated against a pre-specified benchmark derived from the adult placebo remission rate in LUCENT-2 — 50% achieved clinical remission at Week 52, meeting the study's primary endpoint; 81% had achieved clinical response to induction at Week 12
· 50% corticosteroid-free clinical remission without surgery at Week 52
· 73.1% clinical response at Week 52
· 71.2% symptomatic remission at Week 52
· 53.8% endoscopic improvement at Week 52
· 44.2% endoscopic remission at Week 52
· Lilly plans to submit the data to global regulators to support a potential pediatric UC label expansion
Safety: Safety profile consistent with adults, no new signals; most common TEAEs were upper respiratory tract infection, injection site reaction, UC, headache, nasopharyngitis and anemia, mostly mild to moderate; 4 patients (6.3%) had a serious adverse event, none treatment-related; no deaths
Source release →
Eloralintide Phase 2 Positive · 2026-09-30
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego